ParenteralDosed ingredient Cosmetic cross-reference

Thiamine

CAS 59-43-8

Thiamine (CAS 59-43-8) is a Phase 4 pharmaceutical compound with 7 bioactivity targets and 4,733 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

4,733

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Thiamine

CAS Number

59-43-8

UNII

X66NSO3N35

InChIKey

MYVIATVLJGTBFV-UHFFFAOYSA-M

ChEMBL ID

CHEMBL1588

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

Infuvite Pediatric

dosed ingredientnatural productparenteral

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1588 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 12 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	29129.032258064515 nM	31	-
-	Potency	21164.3875 nM	8	-
-	Kd	2468.7402857142856 nM	7	-
-	IC50	17484.206666666665 nM	2	-
-	Kd	17.011 nM	2	-
Thiamine transporter 1 Transporter	-	-	-	Homo sapiens
Transketolase Enzyme	-	-	-	Homo sapiens
Thiamin pyrophosphokinase 1 Kinase	-	-	-	Homo sapiens
Thiamine-triphosphatase Enzyme	-	-	-	Homo sapiens
Transketolase-like protein 1 Enzyme	-	-	-	Homo sapiens
Heat shock protein HSP 90-alpha Cytosolic other	IC50	4.9	-	Homo sapiens
Thiamine transporter ThiT Transporter	Kd	9.91	-	Lactococcus lactis subsp. cremoris

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Pemphigus	5393	2539.936	10034280
Systemic lupus erythematosus	5715	2439.991	10042945
Glossodynia	4952	2135.245	10018388
Hand deformity	4328	1801.007	10061194
Arthropathy	5585	1673.728	10003285
Rheumatoid arthritis	5938	1642.101	10039073
Alopecia	6810	1597.017	10001760
Abdominal discomfort	6922	1532.417	10000059
Wound	4186	1462.246	10052428
Maternal exposure during pregnancy	4754	1418.123	10071408
Completed suicide	179	1363.106	10010144
Toxicity to various agents	1143	1290.96	10070863
Synovitis	4240	1234.968	10042868
Joint swelling	6451	1155.856	10023232
Swelling	5547	1119.013	10042674
Contraindicated product administered	4752	1118.901	10078504
Anti-cyclic citrullinated peptide antibody positive	2939	1116.971	10068798
Discomfort	3837	1072.557	10013082
Pericarditis	3237	1042.8	10034484
Pain	12266	1042.409	10033371
Infusion related reaction	5366	985.223	10051792
Drug abuse	143	911.07	10013654
Death	3536	855.427	10011906
Arthralgia	9761	819.367	10003239
Drug interaction	1668	755.357	10013710
Duodenal ulcer perforation	2095	706.53	10013849
Helicobacter infection	2163	681.471	10054263
Rheumatoid factor positive	1969	672.373	10039080
Psoriatic arthropathy	2240	634.908	10037162
Exposure during pregnancy	3022	623.166	10073513
Musculoskeletal stiffness	3714	610.051	10052904
Hepatic enzyme increased	3876	607.72	10060795
Drug intolerance	5272	550.182	10061822
Intentional overdose	155	548.707	10022523
Product use issue	4398	544.831	10076309
Febrile neutropenia	875	509.886	10016288
Therapeutic product effect decreased	3554	499.121	10082201
Acute kidney injury	2854	436.362	10069339
Nasopharyngitis	4362	394.096	10028810
Disease progression	930	375.228	10061818
Knee arthroplasty	1266	371.801	10023469
Overdose	796	366.568	10033295
Hip arthroplasty	1136	358.341	10020096
Hypersensitivity	4618	347.36	10020751
Treatment failure	3545	344.084	10066901
Suicide attempt	197	343.514	10042464
Foetal exposure during pregnancy	1829	319.468	10071404
Impaired healing	1925	317.418	10021519
Rheumatic fever	970	309.022	10039054
Neutropenia	1693	299.07	10029354

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Thiamine	10454	SU	MTHSPL
THIAMINE	10454	SU	MTHSPL
thiamine	10454	IN	RXNORM
Infuvite Pediatric	1305218	BN	RXNORM

SOURCE SIDER 35 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Agitation	thiamine	LLT	C0085631
Agitation	thiamine	PT	C0085631
Anaphylactic shock	thiamine	LLT	C0002792
Anaphylactic shock	thiamine	PT	C0002792
Angioedema	thiamine	LLT	C0002994
Angioedema	thiamine	PT	C0002994
Asthenia	thiamine	LLT	C0004093
Asthenia	thiamine	PT	C0004093
Collapse	thiamine	LLT	C0344329
Cyanosis	thiamine	LLT	C0010520
Cyanosis	thiamine	PT	C0010520
Feeling hot	thiamine	PT	C2939147
Haemoglobin	thiamine	PT	C0518015
Haemorrhage	thiamine	LLT	C0019080
Haemorrhage	thiamine	PT	C0019080
Hyperhidrosis	thiamine	PT	C0020458
Hypersensitivity	thiamine	LLT	C0020517
Hypersensitivity	thiamine	PT	C0020517
Induration	thiamine	LLT	C0332534
Induration	thiamine	PT	C0332534
Nausea	thiamine	LLT	C0027497
Nausea	thiamine	PT	C0027497
Pruritus	thiamine	LLT	C0033774
Pruritus	thiamine	PT	C0033774
Pulmonary oedema	thiamine	LLT	C0034063
Pulmonary oedema	thiamine	PT	C0034063
Sensation of warmth	thiamine	LLT	C0549386
Shock	thiamine	PT	C0036974
Sweating	thiamine	LLT	C0038990
Tenderness	thiamine	LLT	C0234233
Tenderness	thiamine	PT	C0234233
Throat tightness	thiamine	LLT	C0236071
Throat tightness	thiamine	PT	C0236071
Urticaria	thiamine	LLT	C0042109
Urticaria	thiamine	PT	C0042109

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Thiamine used for in pharmaceutical contexts?

Thiamine (CAS 59-43-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Thiamine?

Thiamine has 4,733 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pemphigus, Systemic lupus erythematosus, Glossodynia, Hand deformity, Arthropathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Thiamine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Thiamine (Vitamin B1) with EU status "permitted".

What clinical phase is Thiamine in?

Thiamine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Thiamine?

Thiamine has 12 bioactivity rows in this page query. Rendered target entries include Thiamine transporter 1, Transketolase, Thiamin pyrophosphokinase 1, Thiamine-triphosphatase, Transketolase-like protein 1.